Twist Bioscience Co. (NASDAQ:TWST) Insider Sells $28,310.37 in Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 709 shares of Twist Bioscience stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $28,310.37. Following the sale, the insider now directly owns 78,996 shares of the company’s stock, valued at approximately $3,154,310.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Dennis Cho also recently made the following trade(s):

• On Tuesday, July 2nd, Dennis Cho sold 126 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total value of $6,048.00.
• On Thursday, June 20th, Dennis Cho sold 234 shares of Twist Bioscience stock. The stock was sold at an average price of $49.41, for a total value of $11,561.94.
• On Friday, June 14th, Dennis Cho sold 95 shares of Twist Bioscience stock. The shares were sold at an average price of $51.04, for a total value of $4,848.80.
• On Thursday, June 6th, Dennis Cho sold 276 shares of Twist Bioscience stock. The shares were sold at an average price of $51.33, for a total value of $14,167.08.

Twist Bioscience Price Performance

NASDAQ TWST traded down $1.45 on Friday, reaching $43.97. The company had a trading volume of 944,659 shares, compared to its average volume of 1,050,882. The firm has a market cap of $2.58 billion, a price-to-earnings ratio of -13.09 and a beta of 1.80. Twist Bioscience Co. has a fifty-two week low of $14.42 and a fifty-two week high of $60.90. The business has a 50 day moving average of $50.93 and a two-hundred day moving average of $41.70.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). The company had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business’s revenue for the quarter was up 27.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.01) earnings per share. As a group, research analysts predict that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. TD Cowen boosted their price target on Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. Evercore ISI boosted their price target on Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Scotiabank boosted their target price on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research note on Monday, May 6th. JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Finally, The Goldman Sachs Group upped their price objective on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, July 9th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $48.22.

Institutional Trading of Twist Bioscience

A number of large investors have recently bought and sold shares of the business. Artisan Partners Limited Partnership grew its holdings in Twist Bioscience by 111.3% during the 4th quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock worth $137,241,000 after acquiring an additional 1,961,621 shares during the period. Nikko Asset Management Americas Inc. boosted its position in shares of Twist Bioscience by 2.9% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company’s stock worth $131,835,000 after purchasing an additional 99,511 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Twist Bioscience by 2.9% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,583,443 shares of the company’s stock worth $132,086,000 after purchasing an additional 99,511 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Twist Bioscience by 29.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock worth $46,732,000 after purchasing an additional 284,884 shares in the last quarter. Finally, Baillie Gifford & Co. boosted its position in shares of Twist Bioscience by 12.1% during the 1st quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company’s stock worth $42,116,000 after purchasing an additional 132,770 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.